PMV Pharma

PMVP

Current ValuationThe current P/E ratio is -1.24, within the reasonable range, cheaper than 33.77% of the time in the past 5 years, and the industry ranks 232/604, the industry Median -1.89.

-1.24xP/E
Stock price$1.24Earnings per share$-1.00

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-58.76x150.48%$190.38B
MRNAUSModerna
-28.67x15.49%$90.35B
CSLLYUSCSL Limited
-23.97x--$61.82B
NTRAUSNatera
-295.83x6.85%$56.90B
RVMDUSRevolution Medicines
-23.46x62.10%$41.48B
ROIVUSRoivant Sciences
-91.21x146.49%$24.28B
BNTXUSBioNTech SE
-11.39x19.07%$22.27B
INSMUSInsmed
-24.40x74.50%$21.36B
BBIOUSBridgebio Pharma
-18.35x28.67%$12.70B
SMMTUSSummit Therapeutics
-14.10x20.67%$12.07B
PCVXUSVaxcyte
-9.99x48.18%$10.63B
MDGLUSMadrigal Pharma
-32.69x51.32%$10.63B
IBRXUSImmunityBio
-10.58x153.51%$10.50B
TWSTUSTwist Bioscience
-71.34x28.71%$9.75B
KYMRUSKymera Therapeutics
-29.65x5.24%$8.88B
CYTKUSCytokinetics
-9.86x6.68%$8.82B
ARWRUSArrowHead Pharma
-25.77x35,923.70%$8.25B
ABVXUSAbivax SA
-16.49x22.49%$7.67B
IONSUSIonis Pharma
-12.56x50.43%$7.10B
SYREUSSpyre Therapeutics
-46.16x45.67%$6.93B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.